Compare · CHPT vs EW
CHPT vs EW
Side-by-side comparison of ChargePoint Holdings Inc. (CHPT) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- CHPT operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $49.83B, about 279.1x CHPT ($178.6M).
- Over the past year, CHPT is down 36.0% and EW is up 21.2% - EW leads by 57.2 points.
- CHPT has been more active in the news (7 items in the past 4 weeks vs 5 for EW).
- Both have 25 recent analyst ratings on file.
- Company
- ChargePoint Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $178.6M
- $49.83B
- 1M return
- -18.76%
- -1.37%
- 1Y return
- -35.96%
- +21.23%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 25
ChargePoint Holdings Inc.
ChargePoint Holdings, Inc. provides electric vehicle (EV) charging networks and charging solutions in the United States. It offers a portfolio of hardware, software, and services for commercial, fleet, and residential customers. The company was founded in 2007 and is headquartered in Campbell, California.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest CHPT
- ChargePoint Holdings Inc. filed SEC Form 8-K: Other Events
- President and CEO Wilmer Richard covered exercise/tax liability with 7,631 shares, decreasing direct ownership by 2% to 496,462 units (SEC Form 4)
- CAO Novruzova Natella Fakhradovna sold $14,632 worth of shares (1,484 units at $9.86), decreasing direct ownership by 5% to 28,213 units (SEC Form 4) (withholding tax)
- CCXO Singh Jagdeep Ca sold $58,815 worth of shares (5,965 units at $9.86), decreasing direct ownership by 3% to 182,381 units (SEC Form 4) to satisfy withholding tax
- General Counsel Batill Eric sold $42,418 worth of shares (4,302 units at $9.86), decreasing direct ownership by 3% to 139,329 units (SEC Form 4) (tax withholding)
- CFO Khetani Mansi sold $48,620 worth of shares (4,931 units at $9.86), decreasing direct ownership by 3% to 174,417 units (SEC Form 4) to cover taxes
- Handshake Unveils AI Skills Studio for Job Seekers: NYSE Content Update
- SEC Form 10-Q filed by ChargePoint Holdings Inc.
- ChargePoint Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ChargePoint Accelerates European Growth Strategy with Appointment of John Saffrett as EVP and Managing Director, Europe
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision